Investing.com - Allarity Therapeutics reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Allarity Therapeutics announced earnings per share of $-0.68 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.25 on revenue of $0.00.
Allarity Therapeutics 's are down 78% and is trading at $0.50 , still down 97.25% from its 52 week high of $18.20 set on Tuesday, December 21, 2021.
Allarity Therapeutics follows other major Healthcare sector earnings this month
Allarity Therapeutics's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar